Cognition Therapeutics (CGTX) announced it has received an anonymous philanthropic donation to substantially fund an expanded access program for people with dementia with Lewy bodies, DLB. The generous donation comes from the family of a DLB patient who was treated with zervimesine in the Phase 2 SHIMMER study. Through this open-label EAP, participants will be provided with 100 mg of oral zervimesine to take daily for approximately one year. Banner Sun Health Research Institute in Arizona is the first of eight sites to be activated, with David Shprecher, DO Msci serving as primary investigator at the site.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics Advances to Phase 3 Trials
- Cognition Therapeutics price target lowered to $3 from $5 at H.C. Wainwright
- Cognition Therapeutics presents preclinical data on zervimesine at ARVO
- Cognition Therapeutics Reports Q1 2025 Financials and Progress
- Cognition Therapeutics reports results from Phase 2 COG2201 trial